Update in Pediatric Infectious Disease

  • Archana Chatterjee
  • Maya Gogoi


Change is common in the field of pediatric infectious diseases with novel and re-emerging infections, the development and implementation of new vaccines and antimicrobial therapies, and the introduction of innovative diagnostic methodology and infection prevention modalities. This chapter provides an overview and brief summary of a selection of emerging issues in pediatric infectious diseases including: the impact of human papillomavirus (HPV) vaccines, despite their relatively poor uptake in the past decade; the ongoing outbreaks of measles in the United States; the rise in Clostridium difficile infections in children; the role of antibiotic stewardship in pediatric facilities; the status and management of methicillin-resistant Staphylococcus aureus (MRSA) infections; the management of congenital cytomegalovirus (CMV) infections; the introduction of meningococcal B vaccines; and the implications of the Zika virus outbreak. This assortment of topics will provide the reader with an understanding of the dynamic and diverse nature of the field of pediatric infectious diseases.


HPV vaccines Measles outbreaks Clostridium difficile infections Antibiotic stewardship Methicillin-resistant Staphylococcus aureus Congenital cytomegalovirus infections Meningococcal B vaccines Zika virus 


  1. Ali H, Donovan B, Wand H, et al. Genital warts in young Australians five years into national human papillomavirus vaccination programme: national surveillance data. BMJ. 2013;346:f2032.PubMedCrossRefGoogle Scholar
  2. Al-Jumaili IJ, Shibley M, Lishman AH, Record CO. Incidence and origin of Clostridium difficile in neonates. J Clin Microbiol. 1984;19:77–8.PubMedPubMedCentralGoogle Scholar
  3. Bai X, Findlow J, Borrow R. Recombinant protein meningococcal serogroup B vaccine combined with outer membrane vesicles. Expert Opin Biol Ther. 2011;11:969–85.PubMedCrossRefGoogle Scholar
  4. Barlam TF, Cosgrove SE, Abbo LM, MacDougall C, Schuetz AN, Septimus EJ, Srinivasan A, Dellit TH, Falck-Ytter YT, Fishman NO, Hamilton CW, Jenkins TC, Lipsett PA, Malani PN, May LS, Moran GJ, Neuhauser MM, Newland JG, Ohl CA, Samore MH, Seo SK, Trivedi KK. Implementing an Antibiotic Stewardship Program: guidelines by the Infectious Diseases Society of America and the Society for Healthcare Epidemiology of America. Clin Infect Dis. 2016;62(10):e51–77.PubMedPubMedCentralCrossRefGoogle Scholar
  5. Bayley N. Bayley Scales of Infant Development technical manual. 3rd ed. Harcourt Assessment: San Antonio, TX; 2006.Google Scholar
  6. Benno Y, Sawada K, Mitsuoka T. The intestinal microflora of infants: composition of fecal flora in breast-fed and bottle-fed infants. Microbiol Immunol. 1984;28(9):975–86.PubMedCrossRefGoogle Scholar
  7. Benson L, Song X, Campos J, Singh N. Changing epidemiology of Clostridium difficile-associated in children. Infect Control Hosp Epidemiol. 2007;28:1233–5.PubMedCrossRefGoogle Scholar
  8. Bhatia N, Lynde C, Vender R, Bourcier M. Understanding genital warts: epidemiology, pathogenesis, and burden of disease of human papillomavirus. J Cutan Med Surg. 2013;17(Suppl 2):S47–54.PubMedGoogle Scholar
  9. Boggan JC, Navar-Boggan AM, Jhaveri R. Pediatric-specific antimicrobial susceptibility data and empiric antibiotic selection. Pediatrics. 2012;130:e615–22.PubMedCrossRefGoogle Scholar
  10. Bonner AB, Monroe KW, Talley LI, Klasner AE, Kimberlin DW. Impact of the rapid diagnosis of influenza on physician decision-making and patient management in the pediatric emergency department: results of a randomized, prospective, controlled trial. Pediatrics. 2003;112:363–7.PubMedCrossRefGoogle Scholar
  11. Boppana SB, Ross SA, Novak Z, et al. Dried blood spot real-time polymerase chain reaction assays to screen newborns for congenital cytomegalovirus infection. JAMA. 2010;303:1375–82.PubMedPubMedCentralCrossRefGoogle Scholar
  12. Boppana SB, Ross SA, Fowler KB. Congenital cytomegalovirus infection: clinical outcome. Clin Infect Dis. 2013;57(Suppl 4):S178–81.PubMedPubMedCentralCrossRefGoogle Scholar
  13. Bosch FX. Human papillomavirus: science and technologies for the elimination of cervical cancer. Expert Opin Pharmacother. 2011;12(14):2189–204.PubMedCrossRefGoogle Scholar
  14. Bosch FX, Castellsague X, de Sanjose S. HPV and cervical cancer: screening or vaccination? Br J Cancer. 2008;98(1):15–21.PubMedPubMedCentralCrossRefGoogle Scholar
  15. Brito C. Zika virus: a new chapter in the history of medicine. Acta Medica Port. 2015;28(6):679–80.CrossRefGoogle Scholar
  16. Broderick M, Faix D, Hansen C, Blair P. Trends in meningococcal disease in the United States military, 1971–2010. Emerg Infect Dis. 2012;18(9):1430–7.PubMedPubMedCentralCrossRefGoogle Scholar
  17. Broutet N, Krauer F, Riesen M, Khalakdina A, Almiron M, Aldighieri S, Espinal M, Low N, Dye C. Zika virus as a cause of neurologic disorders. N Engl J Med. 2016;374(16):1506–9.PubMedCrossRefGoogle Scholar
  18. Bryant K, McDonald LC. Clostridium difficile infections in children. Pediatr Infect Dis J. 2009;28(2):145–6.PubMedCrossRefGoogle Scholar
  19. Byington CL, Castillo H, Gerber K, et al. The effect of rapid respiratory viral diagnostic testing on antibiotic use in a children’s hospital. Arch Pediatr Adolesc Med. 2002;156:1230–4.PubMedCrossRefGoogle Scholar
  20. Cavalheiro S, Lopez A, Serra S, Da Cunha A, da Costa MDS, Moron A, Lederman HM. Microcephaly and Zika virus: neonatal neuroradiological aspects. Childs Nerv Syst. 2016;32:1057–60.PubMedPubMedCentralCrossRefGoogle Scholar
  21. Centers for Disease Control and Prevention (2015) Measles cases and outbreaks. Accessed 10 Jul 2016.Google Scholar
  22. Centers for Disease Control and Prevention. Zika virus: transmission and risks. 2016a. Accessed 12 Jul 2016.Google Scholar
  23. Centers for Disease Control and Prevention. 2016b Zika virus: symptoms, diagnosis, & treatment. Accessed 12 Jul 2016.Google Scholar
  24. Centers for Disease Control and Prevention. 2016c Zika and Guillain-Barré syndrome. Accessed 12 Jul 2016.Google Scholar
  25. Centers for Disease Control and Prevention. Zika virus: clinical guidance. 2016d. Accessed 12 Jul 2016.Google Scholar
  26. Centers for Disease Control and Prevention (CDC). Human papillomavirus vaccination coverage among adolescent girls, 2007-2012, and postlicensure vaccine safety monitoring, 2006–2013 – United States. MMWR Morb Mortal Wkly Rep. 2013;62(29):591–5.Google Scholar
  27. Centers for Disease Control and Prevention (CDC). Core elements of hospital antibiotic stewardship programs. 2014. Accessed 10 Jul 2016.Google Scholar
  28. Chatterjee A. The next generation of HPV vaccines: nonavalent vaccine V503 on the horizon. Expert Rev Vaccines. 2014;13(11):1279–90.PubMedCrossRefGoogle Scholar
  29. Chiem AT. Infectious disease/CDC update. Measles outbreak – California, December 2014–February 2015. Ann Emerg Med. 2015;66(1):82–3.PubMedCrossRefGoogle Scholar
  30. Chiu CH, Michelow IC, Cronin J, Ringer SA, Ferris TG, Puopolo KM. Effectiveness of a guideline to reduce vancomycin use in the neonatal intensive care unit. Pediatr Infect Dis J. 2011;30:273–8.PubMedCrossRefGoogle Scholar
  31. Christensen H, May M, Bowen L, Hickman M, Trotter CL. Meningococcal carriage by age: a systematic review and meta-analysis. Lancet Infect Dis. 2010;10(12):853–61.PubMedCrossRefGoogle Scholar
  32. Clemmons NS, Gastanaduy PA, Fiebelkorn AP, Redd SB. Wallace GS; Centers for Disease Control and Prevention (CDC). Measles – United States, January 4–April 2, 2015. MMWR Morb Mortal Wkly Rep. 2015;64(14):373–6.PubMedPubMedCentralGoogle Scholar
  33. Cohen SH, Gerding DN, Johnson S, et al. Society for Healthcare Epidemiology of America; Infectious Diseases Society of America. Clinical practice guidelines for Clostridium difficile infection in adults: 2010 update by the Society for Healthcare Epidemiology of America (SHEA) and the Infectious Diseases Society of America (IDSA). Infect Control Hosp Epidemiol. 2010;31(5):431–55.PubMedCrossRefGoogle Scholar
  34. Communicable Diseases Network Australia: Commonwealth Department of Health and Ageing. Guidelines for the early clinical and public health management of meningococcal disease in Australia. Revised ed. Canberra, ACT: Communicable Diseases Network Australia: Commonwealth Department of Health and Ageing; 2007.Google Scholar
  35. Cosgrove SE, Sakoulas G, Perencevich EN, Schwaber MJ, Karchmer AW, Carmeli Y. Comparison of mortality associated with methicillin-resistant and methicillin-susceptible Staphylococcus aureus bacteremia: a meta-analysis. Clin Infect Dis. 2003;36(1):53–9.PubMedCrossRefGoogle Scholar
  36. Crobach MJ, Dekkers OM, Wilcox MH, Kuijper EJ. European Society of Clinical Microbiology and Infectious Diseases (ESCMID): data review and recommendations for diagnosing Clostridium difficile-infection (CDI). Clin Microbiol Infect. 2009;15(12):1053–66.PubMedCrossRefGoogle Scholar
  37. Delbos V, Lemée L, Bénichou J, Berthelot G, Taha M, Caron F, B14 STOP Study Group. Meningococcal carriage during a clonal meningococcal B outbreak in France. Eur J Clin Microbiol Infect Dis. 2013;32:1451–9.PubMedCrossRefGoogle Scholar
  38. Di Pentima MC, Chan S, Hossain J. Benefits of a pediatric antimicrobial stewardship program at a children’s hospital. Pediatrics. 2011;128:1062–70.PubMedCrossRefGoogle Scholar
  39. Doan QH, Kissoon N, Dobson S, et al. A randomized, controlled trial of the impact of early and rapid diagnosis of viral infections in children brought to an emergency department with febrile respiratory tract illnesses. J Pediatr. 2009;154:91–5.PubMedCrossRefGoogle Scholar
  40. Donnelly J, Medini D, Boccadifuoco G, Biolchi A, Ward J, Frasch C, et al. Qualitative and quantitative assessment of meningococcal antigens to evaluate the potential strain coverage of protein-based vaccines. Proc Natl Acad Sci U S A. 2010;107(45):19490–5.PubMedPubMedCentralCrossRefGoogle Scholar
  41. Drolet M, Bénard É, Boily MC, et al. Population-level impact and herd effects following human papillomavirus vaccination programmes: a systematic review and meta-analysis. Lancet Infect Dis. 2015;15(5):565–80.PubMedPubMedCentralCrossRefGoogle Scholar
  42. Durand C, Brueckner A, Sampadian C, Willett KC, Belliveau P. Daptomycin use in pediatric patients. Am J Health Syst Pharm. 2014;71(14):1177–82.PubMedCrossRefGoogle Scholar
  43. Enoch DA, Butler MJ, Pai S, Aliyu SH, Karas JA. Clostridium difficile in children: colonisation and disease. J Infect. 2011;63(2):105–13.PubMedCrossRefGoogle Scholar
  44. European Centre for Disease Prevention and Control. Surveillance of invasive bacterial diseases in Europe 2008/2009. Sotckholm: ECDC; 2011.Google Scholar
  45. Findlow J. Meningococcal group B vaccines. Hum Vaccin Immunother. 2013;9(6):1387–8.PubMedPubMedCentralCrossRefGoogle Scholar
  46. Fishman N. Policy statement on amtimicrobial stewardship by the Society for Healthcare Epidemiology of America (SHEA), the Infectious Diseases Society of America (IDSA), and the Pediatric Diseases Society (PIDS). Infect Control Hosp Epidemiol. 2012;33:322–7.CrossRefGoogle Scholar
  47. Folaranmi T, Rubin L, Martin SW, Patel M, JR MN, Centers for Disease Control (CDC). Use of Serogroup B meningococcal vaccines in persons aged ≥10 years at increased risk for serogroup b meningococcal disease: recommendations of the Advisory Committee on Immunization Practices, 2015. MMWR Morb Mortal Wkly Rep. 2015;64(22):608–12.PubMedPubMedCentralGoogle Scholar
  48. Forman D, de Martel C, Lacey CJ, et al. Global burden of human papillomavirus and related diseases. Vaccine. 2012;20(Suppl 5):F12–23.CrossRefGoogle Scholar
  49. Fowler KB, Boppana SB. Congenital cytomegalovirus (CMV) infection and hearing deficit. J Clin Virol. 2006;35:226–31.PubMedCrossRefGoogle Scholar
  50. FUTURE II Study Group. Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions. N Engl J Med. 2007;356(19):1915–27.CrossRefGoogle Scholar
  51. Gerber JS, Coffin SE, Smathers SA, Zaoutis TE. Trends in the incidence of methicillin resistant Staphylococcus aureus infection in children’s hospitals in the United States. Clin Infect Dis. 2009;49(1):65–71.PubMedPubMedCentralCrossRefGoogle Scholar
  52. Goldenberg JZ, Ma SSY, Saxton JD, Martzen MR, Vandvik PO, Thorlund K, Guyatt GH, Johnston BC. Probiotics for the prevention of Clostridium difficile-associated diarrhea in adults and children. Cochrane Database Syst Rev. 2013;5:CD006095.Google Scholar
  53. Gostelow M, Gonzalez D, Smith PB, Cohen-Wolkowiez M. Pharmacokinetics and safety of recently approved drugs used to treat methicillin-resistant Staphylococcus aureus infections in infants, children and adults. Expert Rev Clin Pharmacol. 2014;7(3):327–40.PubMedPubMedCentralCrossRefGoogle Scholar
  54. Grosse SD, Ross DS, Dollard SC. Congenital cytomegalovirus (CMV) infection as a cause of permanent bilateral hearing loss: a quantitative assessment. J Clin Virol. 2008;41:57–62.PubMedCrossRefGoogle Scholar
  55. Hall IC, O’Toole E. Intestinal flora in new-born infants: with a description of a new pathogenic anaerobe, Bacillus difficilis. Am J Dis Child. 1935;49:390–402.CrossRefGoogle Scholar
  56. Halperin SA, Bettinger JA, Greenwood B, Harrison LH, Jelfs J, Ladhani SN, et al. The changing and dynamic epidemiology of meningococcal disease. Vaccine. 2012;30(suppl 2):B26–36.PubMedCrossRefGoogle Scholar
  57. Halsey NA, Salmon DA. Measles at Disneyland, a problem for all ages. Ann Intern Med. 2015;162(9):655–6.PubMedCrossRefGoogle Scholar
  58. Hamborsky J, Kroger A, Wolfe S, editors. Measles: epidemiology and prevention of vaccine-preventable diseases (the pink book). 13th ed. Washington, DC: Public Health Foundation; 2015.Google Scholar
  59. Harrison L, Trotter C, Ramsay M. Global epidemiology of meningococcal disease. Vaccine. 2009;27S:B51–63.CrossRefGoogle Scholar
  60. Herigon JC, Hersh AL, Gerber JS, Zaoutis TE, Newland JG. Antibiotic management of Staphylococcus aureus infections in US children's hospitals, 1999–2008. Pediatrics. 2010;125(6):e1294–300.PubMedCrossRefGoogle Scholar
  61. Iwamoto M, Mu Y, Lynfield R, Bulens SN, Nadle J, Aragon D, Petit S, Ray SM, Harrison LH, Dumyati G, Townes JM, Schaffner W, Gorwitz RJ, Lessa FC. Trends in invasive methicillin-resistant Staphylococcus aureus infections. Pediatrics. 2013;132(4):e817–24.PubMedCrossRefGoogle Scholar
  62. Jafri R, Ali A, Messonnier N, Tevi-Benissan C, Durrheim D, Eskola J, et al. Global epidemiology of invasive meningococcal disease. Popul Health Metrics. 2013;11:17.CrossRefGoogle Scholar
  63. Jangi S, Lamont JT. Asymptomatic colonization by Clostridium difficile in infants: implications for disease in later life. J Pediatr Gastroenterol Nutr. 2010;51(1):2–7.PubMedCrossRefGoogle Scholar
  64. Jemal A, Bray F, Center MM, et al. Global cancer statistics. CA Cancer J Clin. 2011;61(2):69–90.PubMedCrossRefPubMedCentralGoogle Scholar
  65. Jennings LC, Skopnik H, Burckhardt I, Hribar I, Del Piero L, Deichmann KA. Effect of rapid influenza testing on the clinical management of paediatric influenza. Influenza Other Respir Viruses. 2009;3:91–8.PubMedPubMedCentralCrossRefGoogle Scholar
  66. Joura EA, Giuliano AR, Iversen OE, et al. Broad Spectrum HPV Vaccine Study. A 9-valent HPV vaccine against infection and intraepithelial neoplasia in women. N Engl J Med. 2015;372(8):711–23.PubMedCrossRefGoogle Scholar
  67. Kadmon G, Levy I, Mandelboim M, et al. Polymerase-chain-reaction-based diagnosis of viral pulmonary infections in immunocompromised children. Acta Paediatr. 2013;102:e263–8.PubMedCrossRefGoogle Scholar
  68. Kaplan SL, Hulten KG, Gonzalez BE, et al. Three-year surveillance of community acquired Staphylococcus aureus infections in children. Clin Infect Dis. 2005;40(12):1785–91.PubMedCrossRefGoogle Scholar
  69. Katz SL, Hinman AR. Summary and conclusions: measles elimination meeting, 16–17 March 2000. J Infect Dis. 2004;189(Suppl 1):S43–7.PubMedCrossRefGoogle Scholar
  70. Khalaf N, Crews JD, DuPont HL, Koo HL. Clostridium difficile: an emerging pathogen in children. Discov Med. 2012;14(75):105–13.PubMedPubMedCentralGoogle Scholar
  71. Kim J, Smathers SA, Prasad P, Leckerman KH, Coffin S, Zaoutis T. Epidemiological features of Clostridium difficile-associated disease among inpatients at children’s hospitals in the United States, 2001–2006. Pediatrics. 2008;122(6):1266–70.PubMedCrossRefGoogle Scholar
  72. Kimberlin DW, Lin CY, Sánchez PJ, et al. Effect of ganciclovir therapy on hearing in symptomatic congenital cytomegalovirus disease involving the central nervous system: a randomized, controlled trial. J Pediatr. 2003;143:16–25.PubMedCrossRefGoogle Scholar
  73. Kimberlin DW, Acosta EP, Sánchez PJ, et al. Pharmacokinetic and pharmacodynamics assessment of oral valganciclovir in the treatment of symptomatic congenital cytomegalovirus disease. J Infect Dis. 2008;197:836–45.PubMedCrossRefGoogle Scholar
  74. Kimberlin DW, Jester PM, Sánchez PJ, Ahmed A, Arav-Boger R, Michaels MG, Ashouri N, Englund JA, Estrada B, Jacobs RF, Romero JR, Sood SK, Whitworth MS, Abzug MJ, Caserta MT, Fowler S, Lujan-Zilbermann J, Storch GA, RL DB, Han JY, Palmer A, Weiner LB, Bocchini JA, Dennehy PH, Finn A, Griffiths PD, Luck S, Gutierrez K, Halasa N, Homans J, Shane AL, Sharland M, Simonsen K, Vanchiere JA, Woods CR, Sabo DL, Aban I, Kuo H, James SH, Prichard MN, Griffin J, Giles D, Acosta EP, Whitley RJ, National Institute of Allergy and Infectious Diseases Collaborative Antiviral Study Group. Valganciclovir for symptomatic congenital cytomegalovirus disease. N Engl J Med. 2015;372(10):933–43.PubMedPubMedCentralCrossRefGoogle Scholar
  75. Klevens RM, Morrison MA, Nadle J, et al. Active Bacterial Core surveillance (ABCs) MRSA Investigators. Invasive methicillin resistant Staphylococcus aureus infections in the United States. JAMA. 2007;298(15):1763–71.PubMedCrossRefGoogle Scholar
  76. Larson DA, Derkay CS. Epidemiology of recurrent respiratory papillomatosis. APMIS. 2010;118(6–7):450–4.PubMedCrossRefGoogle Scholar
  77. Lessa FC, Edwards JR, Fridkin SK, Tenover FC, Horan TC, Gorwitz RJ. Trends in incidence of late-onset methicillin-resistant Staphylococcus aureus infection in neonatal intensive care units: data from the National Nosocomial Infections Surveillance System, 1995–2004. Pediatr Infect Dis J. 2009;28(7):577–81.PubMedCrossRefGoogle Scholar
  78. Li R, Lu L, Lin Y, Wang M, Liu X. Efficacy and safety of metronidazole monotherapy versus vancomycin monotherapy or combination therapy in patients with Clostridium difficile infection: a systematic review and meta-analysis. PLoS One. 2015;10(10):e0137252.PubMedPubMedCentralCrossRefGoogle Scholar
  79. Liu C, Bayer A, Cosgrove SE, et al. Clinical practice guidelines by the Infectious Diseases Society of America for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children. Clin Infect Dis. 2011;52(3):e18–55.PubMedCrossRefGoogle Scholar
  80. MacNeil JR, Rubin L, Folaranmi T, Ortega-Sanchez IR, Patel M, Martin SW. Use of Serogroup B meningococcal vaccines in adolescents and young adults: recommendations of the Advisory Committee on Immunization Practices, 2015. MMWR Morb Mortal Wkly Rep. 2015;64(41):1171–6.PubMedCrossRefGoogle Scholar
  81. Majumder MS, Cohn EL, Mekaru SR, Huston JE, Brownstein JS. Substandard vaccination compliance and the 2015 measles outbreak. JAMA Pediatr. 2015;169(5):494–5.PubMedPubMedCentralCrossRefGoogle Scholar
  82. Manicklal S, Emery VC, Lazzarotto T, Boppana SB, Gupta RK. The “silent” global burden of congenital cytomegalovirus. Clin Microbiol Rev. 2013;26:86–102.PubMedPubMedCentralCrossRefGoogle Scholar
  83. Markowitz LE, Hariri S, Lin C, et al. Reduction in human papillomavirus (HPV) prevalence among young women following HPV vaccine introduction in the United States, National Health and Nutrition Examination Surveys, 2003–2010. J Infect Dis. 2013;208(3):385–93.PubMedCrossRefGoogle Scholar
  84. Markowitz LE, Dunne EF, Saraiya M, et al. Centers for Disease Control and Prevention (CDC). Human papillomavirus vaccination: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 2014;63(RR-05):1–30.PubMedGoogle Scholar
  85. Markowitz LE, Liu G, Hariri S, Steinau M, Dunne EF, Unger ER. Prevalence of HPV after introduction of the vaccination program in the United States. Pediatrics. 2016;137(3):e20151968.PubMedCrossRefGoogle Scholar
  86. McCarthy M. US sees first measles death in 12 years. BMJ. 2015;351:h3653.PubMedCrossRefGoogle Scholar
  87. McKamy S, Chen T, Lee M, Ambrose PJ. Evaluation of a pediatric continuous infusion vancomycin therapy guideline. Am J Health Syst Pharm. 2012;69:2066–71.PubMedCrossRefGoogle Scholar
  88. Mesher D, Soldan K, Howell-Jones R, et al. Reduction in HPV 16/18 prevalence in sexually active young women following the introduction of HPV immunisation in England. Vaccine. 2013;32:26–32.PubMedPubMedCentralCrossRefGoogle Scholar
  89. Metjian TA, Prasad PA, Kogon A, Coffin SE, Zaoutis TE. Evaluation of an antimicrobial stewardship program at a pediatric teaching hospital. Pediatr Infect Dis J. 2008;27:106–11.PubMedGoogle Scholar
  90. Morinville V, McDonald J. Clostridium difficile-associated diarrhea in 200 Canadian children. Can J Gastroenterol. 2005;19:497–501.PubMedCrossRefGoogle Scholar
  91. Morris O, Tebruegge M, Pallett A, Green SM, Pearson AD, Tuck A, Clarke SC, Roderick P, Faust SN. Clostridium difficile in children: a review of existing and recently uncovered evidence. Adv Exp Med Biol. 2013;764:57–72.PubMedCrossRefGoogle Scholar
  92. Mullett CJ, Evans RS, Christenson JC, Dean JM. Development and impact of a computerized pediatric antiinfective decision support program. Pediatrics. 2001;108:E75.PubMedCrossRefGoogle Scholar
  93. Murki S, Jonnala S, Mohammed F, Reddy A. Restriction of cephalosporins and control of extended spectrum beta-lactamase producing gram negative bacteria in a neonatal intensive care unit. Indian Pediatr. 2010;47:785–8.PubMedCrossRefGoogle Scholar
  94. Newland JG, Stach LM, DeLurgio SA, et al. Impact of a prospective-audit-with feedback antimicrobial stewardship program at a children’s hospital. J Pediatr Infect Dis. 2012;1:179–86.CrossRefGoogle Scholar
  95. Newman RE, Hedican EB, Herigon JC, Williams DD, Williams AR, Newland JG. Impact of a guideline on management of children hospitalized with community acquired pneumonia. Pediatrics. 2012;129:e597–604.PubMedCrossRefGoogle Scholar
  96. Nolan T, O'Ryan M, Wassil J, Abitbol V, Dull P. Vaccination with a multicomponent meningococcal B vaccine in prevention of disease in adolescents and young adults. Vaccine. 2015;33(36):4437–45.PubMedCrossRefGoogle Scholar
  97. Novartis Vaccines and Diagnostics Inc. Bexsero [package insert]. Cambridge, MA: Novartis Vaccines and Diagnostics Inc; 2015. Accessed 11 Jul 2016Google Scholar
  98. Nylund CM, Goudie A, Garza JM, Fairbrother G, Cohen MB. Clostridium difficile infection in hospitalized children in the United States. Arch Pediatr Adolesc Med. 2011;165(5):451–7.PubMedPubMedCentralCrossRefGoogle Scholar
  99. Oliver SE, Cloud GA, Sánchez PJ, et al. Neurodevelopmental outcomes following ganciclovir therapy in symptomatic congenital cytomegalovirus infections involving the central nervous system. J Clin Virol. 2009;46(Suppl 4):S22–6.PubMedPubMedCentralCrossRefGoogle Scholar
  100. Omer SB, Richards JL, Ward M, Bednarczyk RA. Vaccination policies and rates of exemption from immunization, 2005–2011. N Engl J Med. 2012;367(12):1170–1.PubMedCrossRefGoogle Scholar
  101. Paavonen J, Jenkins D, Bosch FX, et al. HPV PATRICIA study group. Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III doubleblind, randomised controlled trial. Lancet. 2007;369(9580):2161–70.PubMedCrossRefGoogle Scholar
  102. Pakakasama S, Surayuthpreecha K, Pandee U, et al. Clinical practice guidelines for children with cancer presenting with fever to the emergency room. Pediatr Int. 2011;53:902–5.PubMedCrossRefGoogle Scholar
  103. Panatto D, Amicizia D, Lai PL, Gasparini R. Neisseria meningitidis B vaccines. Expert Rev Vaccines. 2011;9:1337–51.CrossRefGoogle Scholar
  104. Pant C, Deshpande A, Altaf MA, Minocha A, Sferra TJ. Clostridium difficile infection in children: a comprehensive review. Curr Med Res Opin. 2013;29(8):967–84.PubMedCrossRefGoogle Scholar
  105. Patel SJ, Saiman L. Principles and strategies of antimicrobial stewardship in the neonatal intensive care unit. Semin Perinatol. 2012;36:431–6.PubMedPubMedCentralCrossRefGoogle Scholar
  106. Pendleton A, Kocher MS. Methicillin-resistant Staphylococcus aureus bone and joint infections in children. J Am Acad Orthop Surg. 2015;23(1):29–37.PubMedCrossRefGoogle Scholar
  107. Perrett KP, McVernon J, Richmond PC, Marshall H, Nissen M, August A, Percell S, Toneatto D, Nolan T. Immune responses to a recombinant, four-component, meningococcal serogroup B vaccine (4CMenB) in adolescents: a phase III, randomized, multicentre, lot-to-lot consistency study. Vaccine. 2015;33(39):5217–24.PubMedCrossRefGoogle Scholar
  108. Petersen E, Wilson ME, Touch S, McCloskey B, Mwaba P, Bates M, Dar O, Mattes F, Kidd M, Ippolito G, Azhar EI, Zumla A. Rapid spread of Zika virus in the Americas—implications for public health preparedness for mass gatherings at the 2016 Brazil Olympic Games. Int J Infect Dis. 2016;44:11–5.PubMedCrossRefGoogle Scholar
  109. Peterson LR, Manson RU, Paule SM, Hacek DM, Robicsek A, Thomson RB Jr, Kaul KL. Detection of toxigenic Clostridium difficile in stool samples by real-time polymerase chain reaction for the diagnosis of C. difficile-associated diarrhea. Clin Infect Di. 2007;45:1152–60.CrossRefGoogle Scholar
  110. Phadke VK, Bednarczyk RA, Salmon DA, Omer SB. Association between vaccine refusal and vaccine-preventable diseases in the United States: a review of measles and pertussis. JAMA. 2016;315(11):1149–58.PubMedPubMedCentralCrossRefGoogle Scholar
  111. Plosa EJ, Esbenshade JC, Fuller MP, Weitkamp JH. Cytomegalovirus infection. In: Kimberlin DW, Brady MT, Jackson MA, Long SS, editors. Red Book: 2015 report of the Committee on Infectious Diseases. 30th ed. Elk Grove Village, IL: American Academy of Pediatrics; 2015. p. 317–22.Google Scholar
  112. Pohl JF, Patel R, Zobell JT, Lin E, Korgenski EK, Crowell K, Mackay MW, Richman A, Larsen C, Chatfield BA. Clostridium difficile infection and proton pump inhibitor use in hospitalized pediatric cystic fibrosis patients. Gastroenterol Res Pract. 2011;2011:1–4.CrossRefGoogle Scholar
  113. Reagan-Steiner S, Yankey D, Jeyarajah J, Elam-Evans LD, Singleton JA, Curtis CR, MacNeil J, Markowitz LE, Stokley S. national, regional, state, and selected local area vaccination coverage among adolescents aged 13–17 years—United States, 2014. MMWR Morb Mortal Wkly Rep. 2015;64(29):784–92.PubMedPubMedCentralCrossRefGoogle Scholar
  114. Roche Pharmaceuticals. Valganciclovir package insert. Clifton, NJ: Roche Pharmaceuticals; 2001. Accessed 13 Jul 2016Google Scholar
  115. Roth A, Mercier A, Lepers C, Hoy D, Duituturaga S, Benyon E, Guillaumot L, Souarès Y. Concurrent outbreaks of dengue, chikungunya and Zika virus infections – an unprecedented epidemic wave of mosquito-borne viruses in the Pacific 2012–2014. Eur Secur. 2014;19(41):1–8.Google Scholar
  116. Rouphael N, Stephens D. Neisseria meningitidis: biology, microbiology, and epidemiology. Methods Mol Biol. 2012;799:1–20.PubMedPubMedCentralCrossRefGoogle Scholar
  117. Saini SS, Dutta S, Ray P, Narang A. Short course versus 7-day course of intravenous antibiotics for probable neonatal septicemia: a pilot, open-label, randomized controlled trial. Indian Pediatr. 2011;48:19–24.PubMedCrossRefGoogle Scholar
  118. Saiz J, Vázquez-Calvo Á, Blázquez AB, Merino-Ramos T, Escribano-Romero E, Martín-Acebes MA. Zika virus: the latest newcomer. Front Microbiol. 2016;7:496.PubMedPubMedCentralGoogle Scholar
  119. Salmon DA, Haber M, Gangarosa EJ, Phillips L, Smith NJ, Chen RT. Health consequences of religious and philosophical exemptions from immunization laws: individual and societal risk of measles. JAMA. 1999;282(1):47–53.PubMedCrossRefGoogle Scholar
  120. Samady W, Pong A, Fisher E. Risk factors for the development of Clostridium difficile infection in hospitalized children. Curr Opin Pediatr. 2014;26(5):568–72.PubMedCrossRefGoogle Scholar
  121. Sammons JS, Toltzis P. Recent trends in the epidemiology and treatment of C. difficile infection in children. Curr Opin Pediatr. 2013;25(1):116–21.PubMedCrossRefGoogle Scholar
  122. Sammons JS, Toltzis P. Pitfalls in diagnosis of pediatric Clostridium difficile infection. Infect Dis Clin N Am. 2015;29:465–76.CrossRefGoogle Scholar
  123. Sammons JS, Toltzis P, Zaoutis TE. Clostridium difficile infection in children. JAMA Pediatr. 2013;167(6):567–73.PubMedCrossRefGoogle Scholar
  124. Sandora TJ, Fung M, Flaherty K, Helsing L, Scanlon P, Potter-Bynoe G, Gidengil CA, Lee GM. Epidemiology and risk factors for Clostridium difficile infection in children. Pediatr Infect Dis J. 2011;30:580–4.PubMedCrossRefGoogle Scholar
  125. Schleiss M, Heineman T. C. Progress toward an elusive goal: current status of cytomegalovirus vaccines. Expert Rev Vaccines. 2005;4:381–406.PubMedCrossRefGoogle Scholar
  126. Schutze GE, Willoughby RE, Committee on Infectious Diseases; American Academy of Pediatrics. Clostridium difficile infection in infants and children. Pediatrics. 2013;131(1):196–200.PubMedCrossRefGoogle Scholar
  127. Seib KL, Scarselli M, Comanducci M, Toneatto D, Masignani V. Neisseria meningitidis factor H-binding protein fHbp: a key virulence factor and vaccine antigen. Expert Rev Vaccines. 2015;14(6):841–59.PubMedCrossRefGoogle Scholar
  128. Soeters HM, McNamara LA, Whaley M, Wang X, Alexander-Scott N, Kanadanian KV, Kelleher CM, MacNeil J, Martin SW, Raines N, Sears S, Vanner C, Vuong J, Bandy U, Sicard K, Patel M, Centers for Disease Control (CDC). Serogroup B meningococcal disease outbreak and carriage evaluation at a college – Rhode Island, 2015. MMWR Morb Mortal Wkly Rep. 2015;64(22):606–7.PubMedPubMedCentralGoogle Scholar
  129. Song X, Perencevich E, Campos J, Short BL, Singh N. Clinical and economic impact of methicillin-resistant Staphylococcus aureus colonization or infection on neonates in intensive care units. Infect Control Hosp Epidemiol. 2010;31(2):177–82.PubMedCrossRefGoogle Scholar
  130. Sudenga SL, Royse KE, Shrestha S. Role and uptake of human papillomavirus vaccine in adolescent health in the United States. Adolesc Health Med Ther. 2011;2:63–74.PubMedCentralGoogle Scholar
  131. Sutphen JL, Grand RJ, Flores A, Chang TW, Bartlett JG. Chronic diarrhea associated with Clostridium difficile in children. Am J Dis Child. 1983;137:275–8.PubMedGoogle Scholar
  132. Swami SK, Banerjee R. Comparison of hospital-wide and age and location-stratified antibiograms of S. aureus, E. coli, and S. pneumoniae: age- and location-stratified antibiograms. Spring. 2013;2:63–7.CrossRefGoogle Scholar
  133. Tabrizi SN, Brotherton JM, Kaldor JM, et al. Fall in human papillomavirus prevalence following a national vaccination program. J Infect Dis. 2012;206:1645–51.PubMedCrossRefGoogle Scholar
  134. Tan LK, Carlone GM, Borrow R. Advances in the development of vaccines against Neisseria meningitidis. N Engl J Med. 2010;362:1511–20.PubMedCrossRefGoogle Scholar
  135. The White House. National action plan for combating antibiotic-resistant bacteria. 2015. Accessed 10 Jul 2016.Google Scholar
  136. Toltzis P, Kim J, Dul M, Zoltanski J, Smathers S, Zaoutis T. Presence of the epidemic North American Pulsed Field type 1 Clostridium difficile strain in hospitalized children. J Pediatr. 2009;154(4):607–8.PubMedCrossRefGoogle Scholar
  137. Vardakas KZ, Kontopidis I, Gkegkes ID, Rafailidis PI, Falagas ME. Incidence, characteristics, and outcomes of patients with bone and joint infections due to community-associated methicillin-resistant Staphylococcus aureus: a systematic review. Eur J Clin Microbiol Infect Dis. 2013;32(6):711–21.PubMedCrossRefGoogle Scholar
  138. Walia R, Kunde S, Mahajan L. Fecal microbiota transplantation in the treatment of refractory Clostridium difficile infection in children: an update. Curr Opin Pediatr. 2014;26(5):573–8.PubMedCrossRefGoogle Scholar
  139. Whitney CG, Zhou F, Singleton J, Schuchat A, Centers for Disease Control and Prevention (CDC). Benefits from immunization during the vaccines for children program era – United States, 1994–2013. MMWR Morb Mortal Wkly Rep. 2014;63(16):352–5.PubMedPubMedCentralGoogle Scholar
  140. Wishaupt JO, Russcher A, Smeets LC, Versteegh FG, Hartwig NG. Clinical impact of RT-PCR for pediatric acute respiratory infections: a controlled clinical trial. Pediatrics. 2011;128:e1113–20.PubMedCrossRefGoogle Scholar
  141. World Health Organization. The history of Zika virus. Geneva: World Health Organization; 2016a. Accessed 12 Jul 2016Google Scholar
  142. World Health Organization. Pregnancy management in the context of Zika virus infection: Interim guidance update. Geneva: World Health Organization; 2016b. Accessed 12 Jul 2016Google Scholar
  143. World Health Organization (WHO). Meningococcal vaccines: WHO position paper, November 2011. Wkly Epidemiol Rec. 2011;86(47):521–39.Google Scholar
  144. Wyeth Pharmaceuticals Inc. Trumenba [package insert]. Philadelphia, PA: Wyeth Pharmaceuticals Inc. (Pfizer); 2014. Accessed 11 Jul 2016Google Scholar
  145. Yang YT, Barraza L, Weidenaar K. Measles outbreak as a catalyst for stricter vaccine exemption legislation. JAMA. 2015;314(12):1229–30.PubMedCrossRefGoogle Scholar
  146. Zilberberg MD, Tillotson GS, McDonald C. Clostridium difficile infections among hospitalized children, United States, 1997–2006. Emerg Infect Dis. 2010;16(4):604–9.PubMedPubMedCentralCrossRefGoogle Scholar
  147. Zingg W, Pfister R, Posfay-Barbe KM, Huttner B, Touveneau S, Pittet D. Secular trends in antibiotic use among neonates: 2001–2008. Pediatr Infect Dis J. 2011;30:365–70.PubMedCrossRefGoogle Scholar
  148. Zipprich J, Winter K, Hacker J, Xia D, Watt J, Harriman K, Centers for Disease Control and Prevention (CDC). Measles outbreak—California, December 2014–February 2015. MMWR Morb Mortal Wkly Rep. 2015;64(6):153–4.PubMedPubMedCentralGoogle Scholar

Copyright information

© Springer International Publishing AG, part of Springer Nature 2018

Authors and Affiliations

  1. 1.Department of PediatricsUniversity of South Dakota Sanford School of MedicineSioux FallsUSA

Personalised recommendations